JD HEALTH Aktie

 

Ant Group Co. Ltd. has promoted its healthcare division to a core business segment, marking a major organizational shift that highlights the Chinese fintech giant's deepening push into AI-driven medical services.In an internal memo dated Friday, chief executive Han Xinyi said the company had established a new Health Business Group, calling it a strategic pillar alongside existing segments such as Alipay, Digital Payments, Asset Management and Insurance, and Credit. “AI provides a key path to solving the pain points in social health care, and we are fully committed to pursuing this direction,” Han said in the letter.Zhang Junjie, a longtime executive who joined Ant in 2014 and was among the earliest members of Alipay's medical team, has been appointed president of the new unit. He will report directly to Han.The move formalizes Ant's growing presence in the healthcare sector and positions it more directly against competitors including JD Health, Tencent Holdings Ltd. and Baidu Inc., all of which are...

JD HEALTH (06618.HK) announced yesterday (20th) that it recently partnered with well-known in vitro diagnostics (IVD) brands such as WONDFO (300482.SZ), Abbott Laboratories (ABT.US), COFOE MEDICAL (301087.SZ), INNOVITA (688253.SH) and KANGHUA BIOLOGICAL (300841.SZ) to initiate the 'JDH+N' JD HEALTH medical devices IVD br......

Macquarie has issued a research report anticipating JD HEALTH (06618.HK) to deliver stable performance in 3Q25, driving its 2H25 revenue up by 22% YoY.As the influence of offline pharmacies weakens, JD HEALTH is believed to continue consolidating its position as a major distribution channel for healthcare products, gaining more ......

BofA Securities released a report on JD HEALTH (06618.HK), which remarkably beat forecast for its 1H25 results, whereas the broker anticipated that its 2H25 results will continue to beat. In view of this, BofA Securities revised up JD Health's full-year revenue growth forecast for 2025 from 20% to 22%, and adjusted up operat......

CICC has published a research report predicting that JD HEALTH (06618.HK) may stretch its performance from 1H25 into 3Q25, achieving a revenue growth rate of around 25% YoY.The broker also estimated JD HEALTH's 3Q25 non-IFRS net profit to log around a double-digit YoY growth rate given its ongoing investment in building an o......

Nomura has issued a research report expecting JD HEALTH (06618.HK) to maintain strong growth momentum in total revenue for 3Q25.Supported by expected growth of 30%/ 20%/ 10% in sales of pharmaceuticals/ nutrition/ medical devices, JD HEALTH's 3Q25 total revenue is anticipated to surge by 24% YoY.The report attributed the not......

UBS released a research report anticipating that JD HEALTH (06618.HK) will continue its strong revenue growth momentum from 1H25 (up 24.5% YoY) into 3Q25 (growing over 20%). The growth trend across different product categories will persist, with drugs leading overall growth. Both proprietary and third-party growth seemed strong.......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Following the opening of its first store in Yizhuang, Beijing, JD Aesthetics' second self-operated store on the first floor of Vantone Center at Beijing central business district (CBD) achieved a pre-sale amount exceeding RMB1 million, Chinese media quoted sources close to JD HEALTH (06618.HK) as saying. Benefiting from its ......

The Shanxi Provincial Government organized an elderly car service consumption season event, introducing a 2025 home elderly-friendly renovation product consumption subsidy. The subsidy amount is 30% of the product price, with a total maximum subsidy of RMB18,000. This initiative aims to further promote healthy elderly care consu......

Eli Lilly & Co is partnering with Chinese online healthcare platform JD Health International Inc. to sell its blockbuster drugs for obesity and diabetes online, following in competitors' footsteps to drive sales through direct-to-consumer channels....

JD HEALTH (06618.HK) officially entered into a strategic cooperation agreement with Eli Lilly China on 29 August, as announced by JD HEALTH. Both parties will fully leverage their complementary advantages in ways like brand, product, channel, technology and services to jointly build an integrated management model of 'drug ac......

At close, HSI dropped 93 pts or 0.4% to 25,176. HSTI rose 36 pts or 0.6% to 5,579. HSCEI fell 5 pts or 0.1% to 9,033. Market turnover reached $312.78 billion.Active Heavyweights:TENCENT (00700.HK) closed at $587, down 0.8%BABA (09988.HK) closed at $118.6, up 0.4%XIAOMI (01810.HK) closed at $53.05, up 0.4%PING AN (02318.HK) close......

JD HEALTH (06618.HK) recently held a '2025 China Medical Workers' Day Special Event', where 40 outstanding doctors across China were honored and celebrated on-site, recognizing a group of doctors who have put in efforts in the field of internet healthcare, according to Chinese media.As of the end of June, JD Internet......

According to a Macquarie research report, JD HEALTH (06618.HK) reported a 25% YoY increase in total revenue to RMB35.3 billion, with adjusted operating profit rising by 57%, beating the broker's and the market's expectations by 8% and 11%, respectively.The broker believes that JD HEALTH has reached a turning point in its......

JD HEALTH (06618.HK)'s 1H25 results beat expectations with vigorous drug sales, according to Nomura's research report.The company's revenue grew by 24.5% YoY (implying a 24% YoY growth in 2Q25), surpassing the market's and the broker's estimates by 4% and 3%, respectively. This growth was primarily driven by ......

At midday close, HSI rose 156 pts or 0.6% to 25,426. HSTI rose 108 pts or 2.0% to 5,651. HSCEI gained 91 pts or 1.0% to 9,130.Active Heavyweights:BABA (09988.HK) closed at $120, up 1.6%XIAOMI (01810.HK) closed at $53.7, up 1.6%MEITUAN (03690.HK) closed at $123.4, up 1.4%TENCENT (00700.HK) closed at $594, up 0.3%HSI & HSCEI Const......

JD HEALTH (06618.HK)'s 1H25 revenue soared by 24.5% YoY to RMB35.29 billion, while its non-IFRS net profit surged by 35% YoY to RMB3.57 billion, with a corresponding non-IFRS net profit margin of 10.1%, up 0.8 ppts YoY, beating market expectations, mainly due to strong growth in pharmaceutical categories, according to a CICC......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

JD HEALTH (06618.HK)'s 1H25 results were in line with expectations, with revenue growing by 24.5% YoY to RMB35.3 billion, according to CLSA's research report. Adjusted EBIT rose by 57% YoY to RMB2.5 billion. 2Q25 revenue increased by 24%, maintaining a steady growth rate, mainly benefiting from the strong performance of ......